Şirket yükleniyor
Keep exploring
The themes Sanofi is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The theme it is part of
Highest-graded in Drug Manufacturers General
Graded A or B and worth $2B or more: A first, then the largest.
LLYELI Lilly And Company$1,36TA+
JNJJohnson & Johnson$688,6BA+
MRKMerck & Co., Inc.$364,3BA
NVSNovartis AG$306,3BA
AMGNAmgen Inc.$251,9BA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 Eki 2026CBGraded C, now B
MCKMckesson Corporation4 Kas 2026BAGraded B, now A
CVSCVS Health Corp4 Kas 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 Kas 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 Eki 2026CAGraded C, now A
Nasıl para kazanıyor
- Prescription medicines
- Vaccines
Rekabet ettiği şirketler
Ne satıyor5
Dupixent
A biologic medicine used for several conditions; the call mentions its approval for chronic spontaneous urticaria in children.
ALTUVIIIO
A medicine for hemophilia A, a disorder that affects blood clotting.
AYVAKIT
A medicine used to treat systemic mastocytosis, a rare disease.
2 tane daha göster
Sarclisa
A medicine for multiple myeloma, a cancer of plasma cells.
Wayrilz
A medicine approved in Japan for immune thrombocytopenia, a condition involving low levels of platelets in the blood.
Kim alıyor3
- Patients receive Sanofi medicines through healthcare professionals who prescribe or administer them.
- People receive Sanofi vaccines through healthcare providers and public health programs.
- Pharmacies and clinics are involved in medicine access programs.
Neye dayanıyor ve onu ne yıkabilir
Faaliyetin dayandığı şeyler
- 1Dupixent is developed with Regeneron under an alliance that Sanofi describes as strategically important.
- 2Vaccine sales vary with seasonal demand, including the timing and strength of influenza seasons.
- 3Sanofi depends on clinical studies to show that medicines in development work well enough to advance.
Ters gidebilecekler
- 1Sanofi says its global business exposes it to increased risks in specific areas.
- 2Clinical setbacks have included failed or discontinued studies involving Dupixent in lichen simplex chronicus, venglustat in Fabry disease, and other pipeline medicines.
- 3Sanofi and Regeneron have ongoing litigation over information sharing, while discussions about future collaboration continue without a reported agreement.
Sanofi hakkında
Sanofi makes prescription medicines and vaccines. Its medicines treat conditions including hemophilia A, systemic mastocytosis, and multiple myeloma. It also develops new medicines and vaccines through clinical trials.
- Merkez
- Paris, France
- Kuruluş
- 1973 (founding year, high)
- İşlem gördüğü borsa
- NYSE
- Mali yıl sonu
- December 31
Sanofi şirketinin ABD Menkul Kıymetler ve Borsa Komisyonu’na (SEC) sunduğu kendi belgelerinden kuruldu. Rakamlar bildirildiği gibidir; hisse başına geçmiş bugünkü hisse tabanına göre yeniden hesaplanmıştır. Bu şirket EUR cinsinden raporluyor. Rakamlar güncel kur olan $1,00 = 0,904810 EUR üzerinden, tüm dönemlere aynı şekilde uygulanarak dolara çevrildi — böylece büyüme ve marjlar şirkete ait olur, kura değil. Bu bir işletmeyi anlatır — yatırım tavsiyesi değildir ve alma ya da satma önerisi değildir.
